The Weekly Recap 3/20/26: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, receive regulatory clearances, appoint new executives, and much more on the road to LSI USA ‘26 in Dana Point (March 16–20).

Cognito Therapeutics

Announced new research highlighting its Spectris therapy’s capabilities in Alzheimer’s disease, including findings presented at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases. Results from the OVERTURE feasibility study showed that gamma sensory stimulation delivered through Spectris influenced brain network activity and EEG biomarkers associated with Alzheimer’s, with reductions in EEG slowing correlating with reduced functional decline and brain volume loss.

Endogenex

Announced the publication of 48-week results from the REGENT-1 clinical studies evaluating its pulsed electric field-based technology for type 2 diabetes. The findings showed improvements in glycemic control, body weight, and markers of insulin resistance, along with a favorable safety profile and evidence supporting a dose-response relationship.

Field Medical

Appointed Mark A. Turco, MD, as CEO, effective immediately. Dr. Turco brings more than 30 years of leadership experience spanning venture-backed cardiovascular startups and executive roles within large-cap medical device organizations and will guide the company’s next phase of growth as it advances its FieldForce™ Ablation System for ventricular and atrial arrhythmias.

Ibex Medical Analytics

Announced the launch of Ibex 4, its next-generation AI-powered pathology platform designed to transform the cancer diagnostic workflow. The platform introduces an enhanced user experience and end-to-end breast workflow with automated H&E analysis and “zero-click” IHC quantification, supporting more efficient and accurate scoring of HER2, ER, PR, and Ki67.

Kitea Health

Appointed Harry Rowland, PhD, as Chair of the Board as the company continues to expand its team. Dr. Rowland brings extensive experience scaling medtech companies from innovation through clinical validation, regulatory approval, and commercialization, supporting Kitea Health’s next phase of growth as it advances its remote physiological monitoring technology.

Lenoss Medical

Closed a $6M growth bridge financing round to accelerate commercial expansion, scale operations, and strengthen clinical data generation for its OsteoPearl^Ⓡ platform. The funding includes participation from new and existing investors and follows strong commercial momentum, including record sales and significant growth in surgical procedures.

Monteris Medical

Closed a $28M Series E equity financing round to support technology innovation and accelerate growth initiatives in minimally invasive neurosurgery. The financing will be used to expand the company’s U.S. commercial footprint and accelerate Monteris’ other growth initiatives in technology development, clinical research, and geographic expansion.

Nia Therapeutics

Received FDA Breakthrough Device Designation for its Smart Neurostimulation System, an AI-guided brain implant designed to treat episodic memory loss in adult patients with prior moderate-to-severe traumatic brain injury. The designation supports the company’s path toward an Investigational Device Exemption (IDE) application and a first-in-human early feasibility study.

Perfuze

Received FDA 510(k) clearance for its Millipede88^Ⓡ Aspiration Catheter, the first super-bore aspiration catheter cleared for standalone direct aspiration in stroke treatment. The clearance is supported by independently adjudicated MARRS study data showing a 77% first-pass effect in M1 occlusions and 96% delivery success.

Picard Medical

Announced that a 29-year-old patient successfully received a donor heart transplant after living for more than four years supported entirely by the SynCardia Total Artificial Heart. The company also highlighted a case reported by UCSF Health in which a patient in his twenties with advanced biventricular heart failure was successfully bridged to heart transplantation using the SynCardia Total Artificial Heart. 

Proton Intelligence

Announced that LSI Alumni Dr. Bill Hunter is serving as Board Chair as the company enters its next phase of growth. Dr. Hunter brings experience building sensor-enabled medtech companies and will support Proton Intelligence’s transition from technology development toward clinical adoption of its Continuous Potassium Monitoring (CKM) platform.

QV Bioelectronics

Appointed Carl Daintree as CEO as the company advances its bioelectronic platform for the treatment of brain tumors. Co-Founder Christopher Bullock has transitioned to CTO and will continue to lead the company’s technical and scientific development as it progresses toward regulatory approval.

Revolve Surgical

Received FDA 510(k) clearance for its table-mounted surgical robot platform designed to assist surgeons in minimally invasive procedures. The clearance covers a general surgery indication and supports the company’s plans to use the device as part of initial pilot studies with an expanded clearance for all laparoscopic surgery, expected ahead of its commercial launch.

Sensome

Announced successful proof-of-concept cases using its Clotild^Ⓡ Smart Guidewire System in combination with robotic systems from Robocath to access and characterize clots in cerebral blood vessels. The company says that the results demonstrate the feasibility of using Sensome’s smart guidewire technology with any robotic system accessing the vasculature to provide valuable sensor-obtained biological intelligence that can enhance a procedure.

Surf Therapeutics

Reported positive first-in-human data demonstrating reductions in key inflammatory biomarkers and closed an extension seed financing round, bringing total funding to approximately $6M. The company also officially launched its SUSTAIN early feasibility study evaluating its investigational non-invasive ultrasound neuromodulation therapy for rheumatoid arthritis.

Thrombolex

Closed a $50M Series A financing round led by OrbiMed, with continued support from existing investors. The investment will support expanded commercial reach, continued clinical programs and evidence generation, and organizational growth to support long-term scale.

Veranex

Appointed Megan Osorio as CEO, bringing more than 25 years of leadership experience across the medical device industry. Osorio will lead the company’s next phase of growth as Veranex continues to scale its Innovation CRO (iCRO) model to support medtech innovators from concept through commercialization.

XCath

Successfully completed the world’s first remote robotic intervention in a stroke patient using its Iris Surgical Robotic System, performing a telerobotic mechanical thrombectomy over 200 km away. The milestone demonstrates the potential to expand access to lifesaving stroke treatment by allowing physicians to deliver care remotely.

Xenocor

Appointed David McNally as CEO, alongside Antony Watson as CCO and David Van Ness as CTO. The leadership team will support the commercialization of the company’s FDA 510(k)-cleared Saberscope™ surgical visualization system for minimally invasive and laparoscopic surgery.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.